Weinbrenner S, Assion H-J, Stargardt T, Busse R, Juckel G, Gericke C A
Department of Health Care Management, WHO Collaborating Centre for Health Systems Research and Management, Berlin University of Technology, Berlin, Germany.
Pharmacopsychiatry. 2009 Mar;42(2):66-71. doi: 10.1055/s-0028-1103293. Epub 2009 Mar 23.
The aim of this study was to investigate routine administrative data from a major German health insurance fund, Techniker Krankenkasse, which covers 5.4 million insured individuals. Using a retrospective cohort design, this study analysed data collected from patients with a hospital diagnosis of schizophrenia in 2003 (index hospitalisation) in order to evaluate prescription patterns of antipsychotic drugs.
Patients with an ICD-10 diagnosis of schizophrenia, at least one year prior membership with the insurance fund and a follow-up period of one year were identified. Results were standardised by age and stratified by the severity of their illness, defined by the number of hospital bed days during the three years preceding the index hospitalisation.
A total of 3,121 patients with schizophrenia (male 56.4%, female 43.6%) received 56 692 single prescriptions of antipsychotics. Of these, 35.4% of the prescriptions were for typical and 64.6% for atypical antipsychotics; 55% were for high-potency, 45% for low-potency typical antipsychotics. The most frequently prescribed drugs were olanzapine (26.6%), clozapine (21.3%) and risperidone (19%). There were no relevant gender differences concerning prescription patterns. During a 12-month follow-up period after the first hospitalisation, 1 372 patients (43.9%) were treated exclusively with an atypical antipsychotic, another 499 patients (16%) had a combination of an atypical plus a low-potency typical antipsychotic. Thus, basal therapy with an atypical was observed in 59.9% of our study population. Only 327 patients (10.5%) were treated exclusively with a typical antipsychotic. A total of 645 patients (20.7%) were treated with a combination of atypical plus typical antipsychotic. Changes of medication within one substance group occurred more often with typical antipsychotics (50%) as compared to atypical antipsychotics (25%).
At 60%, the proportion of patients in this study treated with atypical antipsychotics was surprisingly high. Of significant interest is the frequent prescription of clozapine (14%). The results are discussed in comparison to comparable studies from other countries.
本研究旨在调查德国一家大型健康保险基金——技术人员医疗互助会的常规管理数据,该保险涵盖540万参保人员。本研究采用回顾性队列设计,分析了2003年医院诊断为精神分裂症患者(索引住院)的数据,以评估抗精神病药物的处方模式。
确定国际疾病分类第十版(ICD - 10)诊断为精神分裂症、在保险基金至少参保一年且随访期为一年的患者。结果按年龄标准化,并根据索引住院前三年的住院天数定义的疾病严重程度进行分层。
共有3121例精神分裂症患者(男性56.4%,女性43.6%)接受了56692张抗精神病药物的单次处方。其中,35.4%的处方为典型抗精神病药物,64.6%为非典型抗精神病药物;55%为高效能、45%为低效能典型抗精神病药物。最常处方的药物是奥氮平(26.6%)、氯氮平(21.3%)和利培酮(19%)。处方模式方面无相关性别差异。在首次住院后的12个月随访期内,1372例患者(43.9%)仅接受非典型抗精神病药物治疗,另外499例患者(16%)使用非典型加低效能典型抗精神病药物联合治疗。因此,在我们的研究人群中,59.9%观察到以非典型药物作为基础治疗。仅327例患者(10.5%)仅接受典型抗精神病药物治疗。共有645例患者(20.7%)接受非典型加典型抗精神病药物联合治疗。与非典型抗精神病药物(25%)相比,典型抗精神病药物在同一药物组内的用药变化更频繁(50%)。
本研究中接受非典型抗精神病药物治疗的患者比例高达60%,这一比例令人惊讶。值得关注的是氯氮平的频繁处方(14%)。将与其他国家的类似研究结果进行比较讨论这些结果。